{
  "abstract": "Orforglipron, a new glucagon-like peptide-1 (GLP-1) receptor agonist pill, leads to greater glycaemic control and weight loss for patients with type 2 diabetes than oral semaglutide (Rybelsus), researchers have reported.1",
  "authors": [
    {
      "affiliations": [
        "London"
      ],
      "name": "Jacqui Wise"
    }
  ],
  "title": "New weight loss pill outperforms oral semaglutide for diabetes patients, study reports",
  "uid": "ebb2bb6a-5a9e-5d26-9107-31803c1c7a7c"
}